We use cookies to ensure that our site works correctly and provides you with the best experience. If you continue using our site without changing your browser settings, we'll assume that you agree to our use of cookies. Find out more about the cookies we use and how to manage them by reading our cookies policy. Hide

Public Evening Lecture: Professor Paul Workman – Improving the outcome for cancer patients

paul workman pel image

Invitation to SCI’s Free Public Evening Lecture:
Professor Paul Workman – CEO of The Institute of Cancer Research
Improving the outcome for cancer patients

Wednesday 27 February 2019

  • One in two of the UK population will suffer from cancer in their lifetime, with a cancer prognosis made every two minutes in the UK
  • Survival rates are improving but still only 50% of cancer patients survive more than 10 years from diagnosis
  • A combination of innovative targeted therapies are being developed while improving detection methods could greatly improve survival rates

Overall cancer survival rates are rising, but among the 200 known cancers these rates remain relatively poor. The major challenges we face when improving survival rates are the varying cell populations per patient and the emergence of resistance. Using our knowledge of genetics and the biology of cancer, scientists have discovered new drugs that are targeted to specific genetic subtypes. This has evolved into important breakthroughs in stimulating the immune response.

During his Public Evening Lecture, on Wednesday 27 February 2019, Professor Paul Workman will discuss how outcomes will be improved for cancer patients in the future, including developments in early detection, accurate diagnosis and prevention, new therapies for control and cure, and the impact of AI.

About the speaker

Professor Paul Workman is the Chief Executive and President of the Institute of Cancer Research (ICR) in London, where he is also a Harrap Professor of Pharmacology and Therapeutics. From 1997 to 2016, he was Director of the Cancer Research UK Cancer Therapeutics Unit at the ICR – the world’s largest non-profit cancer drug discovery group. Before joining the ICR, Professor Workman spent four years leading cancer research at AstraZeneca and prior to that worked at Glasgow, Stanford, and Cambridge Universities. He was a scientific founder of Piramed Pharma, which was acquired by Roche, and Chroma Therapeutics.

He has been responsible for more than 20 molecularly targeted cancer drugs entering clinical trial, and Professor Workman is especially renowned for his innovative research in the discovery, chemical biology, and molecular pharmacology of drugs and chemical probes acting on highly innovative molecular targets. In 2016, he became a Fellow of the Royal Society.

Date for your diary:     Wednesday 27 February 2019
Venue:                            SCI HQ, 15 Belgrave Square, London SW1X 8PS

Reception opens at 18.00 and the lecture starts at 18.30. This is a free event.

NOTES TO EDITORS

About SCI: where science meets business

The Society of Chemical industry (SCI) is a learned society, established in 1881 specifically to promote the application of science into industry for the benefit of the public. SCI’s founders were scientists, inventors, and entrepreneurs who went on to form industrial businesses at the heart of the 20th Century Industrial Revolution. The society is unique, being a multi-science, multi-disciplinary, and international community. SCI today continues to work at the interface between science and industry, conducting a range of activities that focus on supporting innovation and the commercialisation of science.

MEDIA CONTACT:
SCI Marketing Team
scimarketing@soci.og
+44 (0)207 598 1562 www.soci.org

Related links:

Share this article